BioCryst Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BCRX Nasdaq 2836 www.biocryst.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioCryst Pharmaceuticals, Inc.

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting - May 27th, 2026 5:00 am
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 - May 13th, 2026 5:00 am
BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed? - May 12th, 2026 10:18 am
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing Deal - May 12th, 2026 1:10 am
BioCryst (BCRX) Q1 2026 Earnings Transcript - May 6th, 2026 1:11 pm
BioCryst Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - May 6th, 2026 10:48 am
BioCryst Pharmaceuticals Q1 Earnings Call Highlights - May 6th, 2026 8:55 am
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates - May 6th, 2026 7:30 am
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update - May 6th, 2026 5:00 am
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5th, 2026 5:00 am
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema - May 4th, 2026 5:00 am
Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price Gains - May 3rd, 2026 12:08 pm
RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in Biotech - May 1st, 2026 1:58 am
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too - Apr 29th, 2026 2:03 pm
BioCryst to Present at Upcoming Investor Conferences - Apr 28th, 2026 5:00 am
BioCryst to Report First Quarter 2026 Financial Results on May 6 - Apr 15th, 2026 5:00 am
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer - Apr 6th, 2026 5:00 am
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets - Apr 5th, 2026 1:08 pm
BioCryst Shares Remain Undervalued, RBC Says - Mar 25th, 2026 9:18 am
BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz - Mar 20th, 2026 1:27 am